ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2363

Positivity Of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Is Associated With The Response Rate Of Infliximab, But Not Tocilizumab, In Treatment Of Rheumatoid Arthritis

Masao Sato1, Masao Takemura2, Ryuki Shinohe1, Yasuko Yamamoto3 and Kuniaki Saito3, 1Orthopaedic Surgery, Gifu University, Gifu, Japan, 2Informative Clinical Medicine, Gifu University, Gifu, Japan, 3Human Health Science, Kyoto University, Kyoto, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: ACPA, Rheumatoid Factor and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy III

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Recent reports have shown that positivity for rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) can influence the efficacy of rheumatoid arthritis (RA) treatment. Additionally, RF+ and ACPA+ statuses were emphasized in the revised ACR–EULAR Classification Criteria for Rheumatoid Arthritis. This study examined whether RF+ and ACPA+ statuses in patients with RA impacted the clinical efficacy of anti-TNF-α or anti-IL-6 therapy.

Methods:

We retrospectively evaluated 235 patients with RA who were observed through 52 weeks of follow-up after infliximab (IFX) or tocilizumab (TCZ) treatment at our hospital and related facilities (IFX, n = 142; TCZ, n = 93). Clinical efficacy was assessed based on a 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) remission and achievement of Boolean-based remission criteria and its components (≤1) at 52 weeks after initiating treatment.

Results:

Before treatment, DAS28-ESR score in IFX and TCZ groups was 6.6 ± 1.5 and 6.5 ± 1.3, respectively. The proportion of RF+ and ACPA+ patients was 79.6% and 81.7% in the IFX group and 79.6%, and 87.1% in the TCZ group, respectively. The proportion of patients concomitantly treated with MTX was 100% in the IFX group and 55% in the TCZ group (p < 0.0001); the proportion of patients previously treated with biological products was 0% in the IFX group and 56% in the TCZ group (p < 0.0001). Among patients who achieved remission at 52 weeks in the IFX group, DAS28-ESR remission was seen in 36% and 59% RF+ and RF− patients (p = 0.02), respectively, and in 36% and 62% ACPA+ and ACPA− patients, respectively (p = 0.01). TJC ≤1 was seen in 60% and 89% ACPA+ and ACPA− patients, respectively (p = 0.005) and SJC ≤1 was seen in 60% and 85% ACPA+ and ACPA− patients, respectively (p = 0.01). The proportion of patients who achieved remission was significantly lower in RF+ and ACPA+ patients. In the TCZ group, no efficacy index between RF+ and RF− patients or between ACPA+ and ACPA− patients significantly correlated with remission. Correlations between pretreatment patient demographics and achievement of DAS28 remission at 52 weeks were evaluated. In the IFX group, patients who achieved no remission had higher CRP levels (3.0 vs. 1.9 mg/dL; p = 0.0007), higher disease activity by DAS28-ESR (6.8 vs. 6.2; p = 0.01), and a significantly higher RF+ (86% vs. 71%; p = 0.02) and ACPA+ rates (88% vs. 72%; p = 0.01) than those who achieved remission. However, similar differences were not observed in the TCZ group. A multivariate logistic regression analysis was performed to identify factors related to non-remission at 52 weeks after initiating treatment. DAS28-ESR (OR, 2.24; 95% CI, 1.52–3.47; p = 0.0001) and ACPA+ (OR, 2.82; 95% CI, 1.19–6.97; p = 0.04) were identified as related factors in the IFX group; however, no factors were identified for the TCZ group.

Conclusion:

RF+ and ACPA+ statuses are likely to be risk factors that affect the clinical efficacy of IFX treatment but not TCZ treatment.


Disclosure:

M. Sato,
None;

M. Takemura,
None;

R. Shinohe,
None;

Y. Yamamoto,
None;

K. Saito,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/positivity-of-rheumatoid-factor-and-anti-cyclic-citrullinated-peptide-is-associated-with-the-response-rate-of-infliximab-but-not-tocilizumab-in-treatment-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology